Simone De Nitto, Laura Pighi, Gian Luca Salvagno, Giuseppe Lippi
{"title":"Niveles séricos de antígeno prostático específico (PSA) tras vacunación primaria con BNT162b2","authors":"Simone De Nitto, Laura Pighi, Gian Luca Salvagno, Giuseppe Lippi","doi":"10.1515/almed-2023-0120","DOIUrl":"https://doi.org/10.1515/almed-2023-0120","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"2011 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135346981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Rosado-Jiménez, Younes Mestre-Terkemani, Ángeles García-Aliaga, Miguel Marín-Vera, José Antonio Macías-Cerrolaza, María Desamparados Sarabia-Meseguer, María Rosario García-Hernández, Marta Zafra-Poves, Pilar Sánchez-Henarejos, Francisco Ayala de la Peña, José Luis Alonso-Romero, José Antonio Noguera-Velasco, Francisco Ruiz-Espejo
Abstract Objectives Hereditary breast and ovarian cancer (HBOC) follows an autosomal dominant inheritance pattern of cancer susceptibility genes. The risk of developing this disease is primarily associated with germline mutations in the BRCA1 and BRCA2 genes. The advent of massive genetic sequencing technologies has expanded the mutational spectrum of this hereditary syndrome, thereby increasing the number of variants of uncertain clinical significance (VUS) detected by genetic testing. Methods A prevalence study of HBOC was performed within 2,928 families from the Region of Murcia, in southeastern Spain. Genetic testing enabled the identification of recurrent pathogenic variants and founder mutations, which were mainly related to the BRCA1 and BRCA2 genes. VUS testing was performed using a prioritization algorithm designed by our working group. Results Variants c.68_69del, c.212+1G>A, and c.5123C>A were detected in 30 % of BRCA1 carriers, whereas exon 2 deletion concurrent with c.3264dupT, c.3455T>G and c.9117G>A variants were found in 30 % of BRCA2 carriers. A total of 16 VUS (15 %) were prioritized. Conclusions The genotype-phenotype correlation observed in our study is consistent with the scientific literature. Furthermore, the founder effect of c.1918C>T ( BRCA1 ) and c.8251_8254del ( ATM ) was verified in the Murcian population, whereas exon 2 deletion ( BRCA2 ) was proven to be a Spanish founder mutation. Our algorithm enabled us to prioritize potentially pathogenic VUS that required further testing to determine their clinical significance and potential role in HBOC.
{"title":"Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia","authors":"Laura Rosado-Jiménez, Younes Mestre-Terkemani, Ángeles García-Aliaga, Miguel Marín-Vera, José Antonio Macías-Cerrolaza, María Desamparados Sarabia-Meseguer, María Rosario García-Hernández, Marta Zafra-Poves, Pilar Sánchez-Henarejos, Francisco Ayala de la Peña, José Luis Alonso-Romero, José Antonio Noguera-Velasco, Francisco Ruiz-Espejo","doi":"10.1515/almed-2023-0103","DOIUrl":"https://doi.org/10.1515/almed-2023-0103","url":null,"abstract":"Abstract Objectives Hereditary breast and ovarian cancer (HBOC) follows an autosomal dominant inheritance pattern of cancer susceptibility genes. The risk of developing this disease is primarily associated with germline mutations in the BRCA1 and BRCA2 genes. The advent of massive genetic sequencing technologies has expanded the mutational spectrum of this hereditary syndrome, thereby increasing the number of variants of uncertain clinical significance (VUS) detected by genetic testing. Methods A prevalence study of HBOC was performed within 2,928 families from the Region of Murcia, in southeastern Spain. Genetic testing enabled the identification of recurrent pathogenic variants and founder mutations, which were mainly related to the BRCA1 and BRCA2 genes. VUS testing was performed using a prioritization algorithm designed by our working group. Results Variants c.68_69del, c.212+1G>A, and c.5123C>A were detected in 30 % of BRCA1 carriers, whereas exon 2 deletion concurrent with c.3264dupT, c.3455T>G and c.9117G>A variants were found in 30 % of BRCA2 carriers. A total of 16 VUS (15 %) were prioritized. Conclusions The genotype-phenotype correlation observed in our study is consistent with the scientific literature. Furthermore, the founder effect of c.1918C>T ( BRCA1 ) and c.8251_8254del ( ATM ) was verified in the Murcian population, whereas exon 2 deletion ( BRCA2 ) was proven to be a Spanish founder mutation. Our algorithm enabled us to prioritize potentially pathogenic VUS that required further testing to determine their clinical significance and potential role in HBOC.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135428111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Esra Dönmez, Sevgi Özcan, İrfan Şahin, Ertuğrul Okuyan
Resumen Objetivos Los parámetros hemáticos, como el volumen plaquetario medio (VPM), el índice neutrofilo/linfocito (INL), la amplitud de distribución eritrocitaria (ADE), y la amplitud de distribución plaquetaria (ADP), son indicadores ampliamente utilizados en el pronóstico de diversas patologías cardiovasculares. Investigamos el valor predictivo de los parámetros hemáticos en el desarrollo de nefropatía inducida por contraste (NIC), en pacientes con infarto de miocardio sin elevación del segmento ST (IAMSEST), sometidos a intervención coronaria percutánea (ICP). Métodos Se incluyó retrospectivamente a todos los pacientes diagnosticados de IAMSEST que se sometieron a una ICP percutánea entre 2017 y 2020 en un hospital terciario. Resultados Se incluyó a un total de 387 pacientes. El análisis de regresión logística mostró que la edad avanzada (p=0,001, β:0,005, OR [IC95 %]: 0,002–0,007), la presencia de diabetes mellitus (p=0,013, β:0,205, OR [IC95 %]: 0,150–0,260), insuficiencia cardíaca congestiva (p=0,009, β:0,095, OR [IC95 %]: 0,024–0,166), así como el volumen plaquetario medio (p=0,008, β:0,241, OR [IC95 %]: 0,184–0,392), VPM (p=0,02, β:0,047, OR [IC95 %]: 0,028–0,065), e INL (p=0,001, β:0,052, OR [IC95 %]: 0,040–0,063) fueron factores de riesgo independientes de desarrollar NIC. Un valor umbral de 5,5 para INL mostró una sensibilidad del 79,6 % y una especifidad del 79,5 %, mientras que el valor umbral de 9,05 para el VPM mostró una sensibilidad del 64,1 % y una especifidad del 58,7 % a la hora de predecir el desarrollo de NIC. Conclusiones los parámetros hematológicos, medidos mediante hemograma rutinario, se postulan como marcadores útiles y prometedores de NIC, cuando se emplean en combinación con otros factores de riesgo habituales. El VPM y el INL predicen el desarrollo de NIC en pacientes con IAMSEST sometidos a ICP.
{"title":"Asociación entre parámetros hemáticos y el desarrollo de nefropatía inducida por contraste en pacientes con infarto de miocardio sin elevación del segmento ST","authors":"Esra Dönmez, Sevgi Özcan, İrfan Şahin, Ertuğrul Okuyan","doi":"10.1515/almed-2023-0119","DOIUrl":"https://doi.org/10.1515/almed-2023-0119","url":null,"abstract":"Resumen Objetivos Los parámetros hemáticos, como el volumen plaquetario medio (VPM), el índice neutrofilo/linfocito (INL), la amplitud de distribución eritrocitaria (ADE), y la amplitud de distribución plaquetaria (ADP), son indicadores ampliamente utilizados en el pronóstico de diversas patologías cardiovasculares. Investigamos el valor predictivo de los parámetros hemáticos en el desarrollo de nefropatía inducida por contraste (NIC), en pacientes con infarto de miocardio sin elevación del segmento ST (IAMSEST), sometidos a intervención coronaria percutánea (ICP). Métodos Se incluyó retrospectivamente a todos los pacientes diagnosticados de IAMSEST que se sometieron a una ICP percutánea entre 2017 y 2020 en un hospital terciario. Resultados Se incluyó a un total de 387 pacientes. El análisis de regresión logística mostró que la edad avanzada (p=0,001, β:0,005, OR [IC95 %]: 0,002–0,007), la presencia de diabetes mellitus (p=0,013, β:0,205, OR [IC95 %]: 0,150–0,260), insuficiencia cardíaca congestiva (p=0,009, β:0,095, OR [IC95 %]: 0,024–0,166), así como el volumen plaquetario medio (p=0,008, β:0,241, OR [IC95 %]: 0,184–0,392), VPM (p=0,02, β:0,047, OR [IC95 %]: 0,028–0,065), e INL (p=0,001, β:0,052, OR [IC95 %]: 0,040–0,063) fueron factores de riesgo independientes de desarrollar NIC. Un valor umbral de 5,5 para INL mostró una sensibilidad del 79,6 % y una especifidad del 79,5 %, mientras que el valor umbral de 9,05 para el VPM mostró una sensibilidad del 64,1 % y una especifidad del 58,7 % a la hora de predecir el desarrollo de NIC. Conclusiones los parámetros hematológicos, medidos mediante hemograma rutinario, se postulan como marcadores útiles y prometedores de NIC, cuando se emplean en combinación con otros factores de riesgo habituales. El VPM y el INL predicen el desarrollo de NIC en pacientes con IAMSEST sometidos a ICP.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135428661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The Editorial of the first issue of Adv. Lab. Med. included a description of the goals of this new scientific journal, which comprised achieving a significant presence in impact factor indices [1]. The first step to achieve this goal was to get this journal indexed in the search engines of the most relevant biomedical databases. Otherwise, dissemination would be restricted to a relatively small community of readers. Nowadays, our journal is available on the most important biomedical databases, including PubMed Central (National Center for Biotechnology Information, NCBI); Web of Science (Clarivate Analytics); and Scopus (Elsevier). Hence, search engines provide open access to the works published in our journal to the whole scientific community, which enhances the visibility of our articles. However, it is worth mentioning that, before our journal was included in these search engines, it already received a high number of visits and citations, what demonstrates the quality of and interest raised by our articles. Our journal publishes original articles, systematic reviews and also scientific recommendations submitted by the different Working Groups of the Spanish Society of Laboratory Medicine. The quality and prestige of a scientific journal is measured by a range of quantitative bibliometric indices, which also suggest the difficulty in getting an article published in that journal. The most widely used bibliometric indicator is impact factor (IF), published by the Journal Citation Reports (Clarivate Analytics) on the basis of information available on Web of Science. IF is calculated as the average number of citations of items published in the journal during the preceding two years [2]. Thus, the 2022 IF would correspond to the number of citations of articles published between 2021 and 2020 during 2022, divided by the number of articles published in 2021 and 2020. Another important bibliometric indicator is the position of a journal within its group. In the case of Adv. Lab. Med., this group includes Medical Laboratory Technology, which embraces themost relevant journals in the field of clinical biochemistry, such as Clinical Chemistry or Clinical Chemistry and Laboratory Medicine. Other quality indicators include SCImago Rank (Elsevier), based on the information contained in the Scopus database. The SCImago Journal Rank (SJR) is the alternative quality indicator to IF. This rank is calculated using an algorithm that accounts for the mean number of citations received by a journal during the preceding 3 years during a year and the prestige of the journals where the citations come from. This year, our journal was indexed and ranked by these databases and others, such as Google Scholar Metrics. Regardless of the initial position achieved on bibliometric rankings, fulfilling this goal in such a short period of time was a remarkable success. Of note, our journal was indexed by IF and SJR starting with the first year of publication,which indicates that o
{"title":"A new era for advances in laboratory medicine","authors":"Álvaro González, Roser Ferrer-Costa, Pilar Fernández-Calle, Ignacio Arribas, Wladimiro Jiménez","doi":"10.1515/almed-2023-0116","DOIUrl":"https://doi.org/10.1515/almed-2023-0116","url":null,"abstract":"The Editorial of the first issue of Adv. Lab. Med. included a description of the goals of this new scientific journal, which comprised achieving a significant presence in impact factor indices [1]. The first step to achieve this goal was to get this journal indexed in the search engines of the most relevant biomedical databases. Otherwise, dissemination would be restricted to a relatively small community of readers. Nowadays, our journal is available on the most important biomedical databases, including PubMed Central (National Center for Biotechnology Information, NCBI); Web of Science (Clarivate Analytics); and Scopus (Elsevier). Hence, search engines provide open access to the works published in our journal to the whole scientific community, which enhances the visibility of our articles. However, it is worth mentioning that, before our journal was included in these search engines, it already received a high number of visits and citations, what demonstrates the quality of and interest raised by our articles. Our journal publishes original articles, systematic reviews and also scientific recommendations submitted by the different Working Groups of the Spanish Society of Laboratory Medicine. The quality and prestige of a scientific journal is measured by a range of quantitative bibliometric indices, which also suggest the difficulty in getting an article published in that journal. The most widely used bibliometric indicator is impact factor (IF), published by the Journal Citation Reports (Clarivate Analytics) on the basis of information available on Web of Science. IF is calculated as the average number of citations of items published in the journal during the preceding two years [2]. Thus, the 2022 IF would correspond to the number of citations of articles published between 2021 and 2020 during 2022, divided by the number of articles published in 2021 and 2020. Another important bibliometric indicator is the position of a journal within its group. In the case of Adv. Lab. Med., this group includes Medical Laboratory Technology, which embraces themost relevant journals in the field of clinical biochemistry, such as Clinical Chemistry or Clinical Chemistry and Laboratory Medicine. Other quality indicators include SCImago Rank (Elsevier), based on the information contained in the Scopus database. The SCImago Journal Rank (SJR) is the alternative quality indicator to IF. This rank is calculated using an algorithm that accounts for the mean number of citations received by a journal during the preceding 3 years during a year and the prestige of the journals where the citations come from. This year, our journal was indexed and ranked by these databases and others, such as Google Scholar Metrics. Regardless of the initial position achieved on bibliometric rankings, fulfilling this goal in such a short period of time was a remarkable success. Of note, our journal was indexed by IF and SJR starting with the first year of publication,which indicates that o","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"195 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135255514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leandra J. Robles Navas, Juan J. Ortega Huete, María L. Juliá Sanchis, Jorge S. Bravo Miró, Serezade Cervera Sánchez, Ricardo Molina Gasset
Resumen Objetivos Se realizó un estudio para evaluar la inmunidad de trabajadores sanitarios y no sanitarios del área de salud de Alcoy (España), tras haber recibido tres dosis de la vacuna de Pfizer-BioNTech y analizar su relación con factores individuales. Métodos Se llevó a cabo un estudio prospectivo, observacional, longitudinal, analítico, destinado a observar la inmunogenicidad en profesionales sanitarios y no sanitarios del Hospital Virgen de los Lirios, posterior a la administración de tres dosis de la vacuna de Pfizer-BioNTech. Se determinó la concentración de anticuerpos IgG frente a la proteína spike del SARS-CoV-2. La presencia de COVID-19 se identificó mediante detección cualitativa de anticuerpos IgG contra la proteína de la nucleocápside. Las muestras de los voluntarios se analizaron a los 15 días, 3 meses, y 6 meses de recibir la segunda dosis de la vacuna, y a los 12 meses de la tercera dosis (dosis de refuerzo). Se extrajeron datos demográficos, así como sobre factores de riesgo y el uso de fármacos inmunosupresores. Los análisis estadísticos se realizaron con el programa SPSS. Los niveles medios de anticuerpos a lo largo del tiempo se compararon mediante ANOVA. Resultados La participación fue del 99,5 % (199/200). Las concentraciones de IgG fueron superiores en los hombres y en los sujetos obesos. No se observaron variaciones significativas con respecto a factores como el hábito tabáquico. Conclusiones Todos los participantes desarrollaron inmunidad humoral, excepto tres sujetos, que estaban recibiendo un tratamiento inmunosupresor. Los participantes con infección previa de COVID-19 presentaron mayores niveles de anticuerpos.
本研究的目的是评估在西班牙阿尔科伊(Alcoy)地区接受三剂Pfizer-BioNTech疫苗后的卫生工作者和非卫生工作者的免疫力，并分析其与个体因素的关系。方法:我们进行了一项前瞻性、观察性、纵向分析性研究，旨在观察百合Virgen de los Lirios医院的卫生和非卫生专业人员在给药三剂辉瑞生物技术疫苗后的免疫原性。检测SARS-CoV-2 spike蛋白的IgG抗体浓度。通过对核衣壳蛋白的IgG抗体的定性检测确定了COVID-19的存在。志愿者的样本分别在接种第二次疫苗后15天、3个月和6个月以及接种第三次(强化)疫苗后12个月进行分析。本研究的目的是评估一种免疫抑制药物的使用情况，该药物是一种免疫抑制药物。采用SPSS软件进行统计分析。采用方差分析比较平均抗体水平随时间的变化。结果投票率为99.5%(199/200)。男性和肥胖受试者的IgG浓度较高。在吸烟习惯等因素上没有观察到显著差异。结论:除3名接受免疫抑制治疗的受试者外，所有参与者均出现体液免疫。既往感染COVID-19的参与者抗体水平较高。
{"title":"Estudio longitudinal de la respuesta de anticuerpos tras la vacunación contra el SARS-CoV-2 con la vacuna BNT162b2 de Pfizer-BioNtech","authors":"Leandra J. Robles Navas, Juan J. Ortega Huete, María L. Juliá Sanchis, Jorge S. Bravo Miró, Serezade Cervera Sánchez, Ricardo Molina Gasset","doi":"10.1515/almed-2023-0121","DOIUrl":"https://doi.org/10.1515/almed-2023-0121","url":null,"abstract":"Resumen Objetivos Se realizó un estudio para evaluar la inmunidad de trabajadores sanitarios y no sanitarios del área de salud de Alcoy (España), tras haber recibido tres dosis de la vacuna de Pfizer-BioNTech y analizar su relación con factores individuales. Métodos Se llevó a cabo un estudio prospectivo, observacional, longitudinal, analítico, destinado a observar la inmunogenicidad en profesionales sanitarios y no sanitarios del Hospital Virgen de los Lirios, posterior a la administración de tres dosis de la vacuna de Pfizer-BioNTech. Se determinó la concentración de anticuerpos IgG frente a la proteína spike del SARS-CoV-2. La presencia de COVID-19 se identificó mediante detección cualitativa de anticuerpos IgG contra la proteína de la nucleocápside. Las muestras de los voluntarios se analizaron a los 15 días, 3 meses, y 6 meses de recibir la segunda dosis de la vacuna, y a los 12 meses de la tercera dosis (dosis de refuerzo). Se extrajeron datos demográficos, así como sobre factores de riesgo y el uso de fármacos inmunosupresores. Los análisis estadísticos se realizaron con el programa SPSS. Los niveles medios de anticuerpos a lo largo del tiempo se compararon mediante ANOVA. Resultados La participación fue del 99,5 % (199/200). Las concentraciones de IgG fueron superiores en los hombres y en los sujetos obesos. No se observaron variaciones significativas con respecto a factores como el hábito tabáquico. Conclusiones Todos los participantes desarrollaron inmunidad humoral, excepto tres sujetos, que estaban recibiendo un tratamiento inmunosupresor. Los participantes con infección previa de COVID-19 presentaron mayores niveles de anticuerpos.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"79 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-14DOI: 10.21203/rs.3.rs-3044047/v1
S. De Nitto, L. Pighi, G. Salvagno, G. Lippi
We retrospectively analyzed 37 male healthy employees (mean age: 61±8 years) of the Pederzoli Hospital in Peschiera del Garda (Verona, Italy) who completed a primary vaccination cycle with the COVID-19 vaccine BNT162b2. Blood samples were drawn by standard venipuncture immediately before the first BNT162b2 dose, 21 days thereafter and thus immediately before the second BNT162b2 dose, and 1 month after the second vaccine dose (i.e., 50 days after the first BNT162b2 dose). Serum PSA levels were not significantly different from baseline (median: 0.9 ng/mL; IQR: 0.61-1.88 ng/mL) after the first BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.48-1.26 ng/mL; p=0.074), and were even lower than at baseline after the second BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.39-1.29 ng/mL; p=0.001). Our results suggest that the BNT162b2 vaccine may also have a beneficial effect on prostate biology and function, by reducing circulating PSA levels.
{"title":"Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2","authors":"S. De Nitto, L. Pighi, G. Salvagno, G. Lippi","doi":"10.21203/rs.3.rs-3044047/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-3044047/v1","url":null,"abstract":"We retrospectively analyzed 37 male healthy employees (mean age: 61±8 years) of the Pederzoli Hospital in Peschiera del Garda (Verona, Italy) who completed a primary vaccination cycle with the COVID-19 vaccine BNT162b2. Blood samples were drawn by standard venipuncture immediately before the first BNT162b2 dose, 21 days thereafter and thus immediately before the second BNT162b2 dose, and 1 month after the second vaccine dose (i.e., 50 days after the first BNT162b2 dose). Serum PSA levels were not significantly different from baseline (median: 0.9 ng/mL; IQR: 0.61-1.88 ng/mL) after the first BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.48-1.26 ng/mL; p=0.074), and were even lower than at baseline after the second BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.39-1.29 ng/mL; p=0.001). Our results suggest that the BNT162b2 vaccine may also have a beneficial effect on prostate biology and function, by reducing circulating PSA levels.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48534846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simone De Nitto, Laura Pighi, Gian Luca Salvagno, Giuseppe Lippi
We retrospectively analyzed 37 male healthy employees (mean age: 61±8 years) of the Pederzoli Hospital in Peschiera del Garda (Verona, Italy) who completed a primary vaccination cycle with the COVID-19 vaccine BNT162b2. Blood samples were drawn by standard venipuncture immediately before the first BNT162b2 dose, 21 days thereafter and thus immediately before the second BNT162b2 dose, and 1 month after the second vaccine dose (i.e., 50 days after the first BNT162b2 dose). Serum PSA levels were not significantly different from baseline (median: 0.9 ng/mL; IQR: 0.61-1.88 ng/mL) after the first BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.48-1.26 ng/mL; p=0.074), and were even lower than at baseline after the second BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.39-1.29 ng/mL; p=0.001). Our results suggest that the BNT162b2 vaccine may also have a beneficial effect on prostate biology and function, by reducing circulating PSA levels.
{"title":"Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2","authors":"Simone De Nitto, Laura Pighi, Gian Luca Salvagno, Giuseppe Lippi","doi":"10.1515/almed-2023-0076","DOIUrl":"https://doi.org/10.1515/almed-2023-0076","url":null,"abstract":"We retrospectively analyzed 37 male healthy employees (mean age: 61±8 years) of the Pederzoli Hospital in Peschiera del Garda (Verona, Italy) who completed a primary vaccination cycle with the COVID-19 vaccine BNT162b2. Blood samples were drawn by standard venipuncture immediately before the first BNT162b2 dose, 21 days thereafter and thus immediately before the second BNT162b2 dose, and 1 month after the second vaccine dose (i.e., 50 days after the first BNT162b2 dose). Serum PSA levels were not significantly different from baseline (median: 0.9 ng/mL; IQR: 0.61-1.88 ng/mL) after the first BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.48-1.26 ng/mL; p=0.074), and were even lower than at baseline after the second BNT162b2 dose (median: 0.7 ng/mL; IQR: 0.39-1.29 ng/mL; p=0.001). Our results suggest that the BNT162b2 vaccine may also have a beneficial effect on prostate biology and function, by reducing circulating PSA levels.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135208896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"La sobreexpresión de FoxO1 en el hígado esta positivamente asociada al grado de daño hepático en pacientes cirróticos.","authors":"Esther Fernández-Galán, Silvia Sandalinas, Laura Macias-Muñoz, Irene Portolés, Jordi Ribera, Blai Morales-Romero, Montse Pauta, Gregori Casals, Loreto Boix, Wladimiro Jiménez, Manuel Morales-Ruiz","doi":"10.1515/almed-2023-0054","DOIUrl":"10.1515/almed-2023-0054","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"0 1","pages":"227-235"},"PeriodicalIF":0.0,"publicationDate":"2023-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41441429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Chronic liver disease and related complications, cirrhosis and hepatocellular carcinoma, are associated with high mortality. Curative treatments, partial hepatectomy or liver transplantation, have limited applicability in patients with cirrhosis due to the poor liver regenerative capacity. Thus, we need to find new diagnostic and therapeutic alternatives, to block the disease progression and to improve the survival of patients. In this context, preclinical studies have demonstrated the key role of the protein kinase B (Akt) in liver dysfunction, but the status of Akt and its targets in patients with chronic hepatopathy remains unknown. Aims: To determine the activation status of the Akt pathway and their association with liver functionality in cirrhotic patients.
Methods: This retrospective study includes liver tissue samples from 36 hepatectomized patients with (n=27) and without (n=9) cirrhosis. Multiplex analysis of proteins involved in the Akt/mTOR pathway was performed using a Luminex panel and Western blot. Conventional liver function tests were determined in serum before resection surgery.
Results: Akt and forkhead box protein O1 (FoxO1) are overexpressed in the liver of cirrhotic patients: (2.1 vs. 1.0 densitometric relative units (DRU); p<0.01, and 9.5 vs. 4.4 DRU; p<0.01, respectively). FoxO1 showed the best correlation with markers of liver injury (aspartate aminotransferase (ASAT): r=0.51, p<0.05; alanine aminotransferase (ALAT): r=0.49, p<0.05), and was the only enzyme in the Akt pathway identified as an independent predictor of ASAT and ALAT levels.
Conclusions: The intrahepatic expression of FoxO1 could have clinical utility as a potential prognostic marker for patients with advanced liver disease.
目的：慢性肝病及相关并发症（肝硬化和肝细胞癌）与高死亡率有关。由于肝脏再生能力差，肝部分切除术或肝移植等治疗方法对肝硬化患者的适用性有限。因此，我们需要找到新的诊断和治疗方法，阻止疾病进展，提高患者生存率。在这种情况下，临床前研究已经证明了蛋白激酶 B（Akt）在肝功能异常中的关键作用，但慢性肝病患者体内 Akt 及其靶点的状况仍然未知。目的：确定肝硬化患者体内Akt通路的激活状态及其与肝功能的关系：这项回顾性研究包括 36 名肝硬化患者（27 人）和非肝硬化患者（9 人）的肝组织样本。使用 Luminex 面板和 Western 印迹对参与 Akt/mTOR 通路的蛋白质进行了多重分析。切除手术前对血清中的常规肝功能检测进行了测定：结果：Akt和叉头盒蛋白O1（FoxO1）在肝硬化患者的肝脏中过度表达：(2.1 vs. 1.0密度测定相对单位（DRU）；p. 4.4 DRU；p结论：肝内 FoxO1 的表达可作为晚期肝病患者的潜在预后标志物，具有临床实用性。
{"title":"Liver FoxO1 overexpression is positively associated with the degree of liver injury in cirrhotic patients.","authors":"Esther Fernández-Galán, Silvia Sandalinas, Laura Macias-Muñoz, Irene Portolés, Jordi Ribera, Blai Morales-Romero, Montse Pauta, Gregori Casals, Loreto Boix, Wladimiro Jiménez, Manuel Morales-Ruiz","doi":"10.1515/almed-2023-0014","DOIUrl":"https://doi.org/10.1515/almed-2023-0014","url":null,"abstract":"<p><strong>Objectives: </strong>Chronic liver disease and related complications, cirrhosis and hepatocellular carcinoma, are associated with high mortality. Curative treatments, partial hepatectomy or liver transplantation, have limited applicability in patients with cirrhosis due to the poor liver regenerative capacity. Thus, we need to find new diagnostic and therapeutic alternatives, to block the disease progression and to improve the survival of patients. In this context, preclinical studies have demonstrated the key role of the protein kinase B (Akt) in liver dysfunction, but the status of Akt and its targets in patients with chronic hepatopathy remains unknown. Aims: To determine the activation status of the Akt pathway and their association with liver functionality in cirrhotic patients.</p><p><strong>Methods: </strong>This retrospective study includes liver tissue samples from 36 hepatectomized patients with (n=27) and without (n=9) cirrhosis. Multiplex analysis of proteins involved in the Akt/mTOR pathway was performed using a Luminex panel and Western blot. Conventional liver function tests were determined in serum before resection surgery.</p><p><strong>Results: </strong>Akt and forkhead box protein O1 (FoxO1) are overexpressed in the liver of cirrhotic patients: (2.1 vs. 1.0 densitometric relative units (DRU); p<0.01, and 9.5 vs<i>.</i> 4.4 DRU; p<0.01, respectively). FoxO1 showed the best correlation with markers of liver injury (aspartate aminotransferase (ASAT): r=0.51, p<0.05; alanine aminotransferase (ALAT): r=0.49, p<0.05), and was the only enzyme in the Akt pathway identified as an independent predictor of ASAT and ALAT levels.</p><p><strong>Conclusions: </strong>The intrahepatic expression of FoxO1 could have clinical utility as a potential prognostic marker for patients with advanced liver disease.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 3","pages":"218-226"},"PeriodicalIF":0.0,"publicationDate":"2023-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10701502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：